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Background: Despite the extensive use of chromosomal microarray technologies in patients with
neurodevelopmental disorders has permitted the identification of an increasing number of causative
submicroscopic rearrangements throughout the genome, constitutional duplications involving chromosome 1q22
have seldom been described in those patients.
Results: We report on a pedigree with seven affected members showing varying degrees of behavioural and
emotional disturbances including general anxiety disorder, mood disorders, and intellectual disability. Two adult
female patients also showed late onset autoimmune inflammatory responses characterized by alopecia, skin ulcers
secondary to inflammatory vasculitis, interstitial lung disease, and Raynaud ? s phenomenon. Array-CGH analysis
identified in the affected individuals a 290 Kb microduplication in the chromosome 1q22. The rearrangement
involves eleven known genes and is not present in the databases of polymorphic copy number variants.
Conclusions: The rearrangement segregates with the neurological clinical features observed in our patients,
suggesting that dosage imbalance of one or more genes in this genomic region may lead to the observed
phenotype. The association between the microduplication and the inflammatory disease is much less evident.
Additional reported patients carrying similar microduplications are needed to clarify this aspect.
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In recent years, chromosomal microarray technologies
(CMA) have allowed the identification of an increasing
number of submicroscopic chromosomal deletions and
duplications, called copy number variations (CNV), as-
sociated with a variety of disorders, including intellectual
disability, neuropsychiatric disturbances, and congenital
developmental anomalies. Indeed, in subjects where no
clear genotype/phenotype correlation exists, CMA actually
represents the first-tier genome-wide diagnostic test [1].* Correspondence: marco.fichera@unict.it
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unless otherwise stated.Despite the worldwide constant increase in CMA test-
ing both for clinical and for research purposes, has
allowed an exponential accumulation of knowledge in
this field, the clinical interpretation of the CNVs identi-
fied during the diagnostic setting may still represents a
challenge as many candidate rearrangements are rare
variants never associated with a clinical condition. More-
over, as demonstrated by studies on large cohorts of
healthy and affected individuals, an increasing number
of CNVs are low-penetrant, risk factors for several
diseases. In this context, rare CNVs are often classified
as VOUS (variant of unknown significance) whose exact
role remains to be defined by further studies.
Here we report on a rare 1q22 microduplication
identified in a young boy with intellectual disability andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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analysis demonstrated that the rearrangement segregated
with the disease in the family and that two adult female
patients also presented with clear signs of a systemic
inflammatory disease. We also discuss the potential role
of the microduplication both in the neurodevelopmental
and inflammatory disorders.
Case presentation
Four subjects (3 males), with age ranging from 6 to
16 years were studied. They include one sib pair, a first
cousin and one uncle from the maternal side (Figure 1).
The proband (III-2), a 11-year-old boy, came to our
observation at age 6 because of behavioral disturbances
and global developmental delay. He was born to unre-
lated parents and his pre- and perinatal histories were
unremarkable. He walked unsupported at 24 months
and produced a two-word sentence after the age 3 years.
As a toddler he showed hyperactivity and opposition-
defiant disorder (ODD), aggressive and destructive
behavior. Physical and neurological examinations were
unremarkable. Routine analyses, chromosomal analyses,
FMR1 gene molecular analyses and screening for neuro-
metabolic disorders were normal. Brain MRI, EEG, ABR,
VEP, EMG and repeated EEG evaluations yielded normal
results. He had moderate intellectual disability (WISC-
III total IQ score: 46). At present time (age 11 years), he
shows a significant impairment of adaptive behavior
and psychiatric disturbances with anxiety and depres-
sive symptoms and rule-breaking and aggressive behav-
ior. The younger brother of the proband (III-3) and two
other relatives (III-5, II-10) came to our observationFigure 1 Pedigree of family members with 1q22 microduplication. Indbecause of developmental delay and/or behavioral distur-
bances. Neurocognitive profile and behavioral features of
all studied subjects are reported in Table 1. Cognitive
levels were measured by Wechsler Intelligence Scales for
Children-III (WISC-III), and/or Leiter-R scales and in-
dicated normal to moderate cognitive impairment. Psy-
chiatric symptoms were featured by Children Behavior
Check-list (CBCL) questionnaire filled by both parents
and using a semistructured psychiatric interview: K-
SADS PL that indicated attention deficit, disthymic dis-
order, generalized anxiety disorder, oppositive-defiant
disorder and conduct disorder with rage episodes. All
patients had a CBCL total problem T-score in the clin-
ical range (≥ 70), that was not related to the presence
and/or degree of intellectual disability. Internalizing
T-scores exceeding the borderline or clinical cut-off points
for psychiatric disturbances. In all emotional symptomatol-
ogy was reflected by abnormal scores in the withdrawn,
somatic complain and anxious/depressed scales. In
addition, two subjects (III-2, III-5) had significant external-
izing symptoms with clinically abnormal scores in the
aggressive and rule-breaking behavior symptom scales and
they encountered criteria for CBCL-Severe Dysregulation
profile defined by a score of ≥210 (2 SDs) on the sum of
the Attention, Aggression, and Anxious/Depressed CBCL
scales [2]. Adult subjects (I-2, II-2, II-4) refused a formal
psychiatric interview although they clearly manifested
rapid changes of mood and restless speaking and had been
following medical treatment for depressive disorder. More-
over, individual II-2 presented to our clinic with recurrent
fever (38?-39?C), continuous pain, several superficial skin
damages both in the arms and legs (Figure 2). Skinividuals without genotypes were not available for genetic testing.
Table 1 Neurocognitive and psychiatric symptoms (CBCL
T-scores)
Patient/age III-2/11y III-3/6y III-5/10y II-10/16y
IQ 46 75 88 52
Total 75 70 78 70
Internalizing 68 65 75 70
Externalizing 77 59 76 61
Anxious/depressed (int) 64 57 80 68
Withdrawn (int) 68 66 60 78
Somatic complaints (int) 64 64 73 61
Social problems 70 70 75 77
Thought problems 67 70 83 63
Attention problems 71 69 84 62
Rule? breaking
behavior (ext)
80 53 73 57
Aggressive behavior (ext) 75 61 78 63
Borderline cut-off: score: ≥ 65; Clinical cut-off score: ≥ 70.
Int, symptom scale included in the internalizing broad-band score; Ext, symptom
scale included in the externalizing broad-band score.
(Abnormal scores are in bold character).
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any pathological findings while a skin biopsy demonstrated
clear signs of arteriolar vasculitis. The corticosteroid ther-
apy and vasoactive drugs (Pentoxyphilline) were effective
both in reducing the pain and also in recovering skin
lesions. Her sister (II-4) suffered from a chronic inflamma-
tory disease with microcirculatory damage (i.e. progressive
systemic sclerosis) and treated with anti-inflammatory drug
(low dose of cortichosteroids).
Results
Conventional G-banding karyotype analysis of the proposi-
tus (III-2) showed normal male karyotype (46, XY), while
microarray analysis revealed an interstitial microduplicationFigure 2 Skin lesions in patient II-2. A) Lower limbs. B) Hands.of about 290 kb in the chromosome 1q22: arr 1q22
(155.901.586x2, 155.907.817-156.195.054x3, 156.210.558x2)
hg19) (Figure 3A). The duplication was also present in
Individuals I-2, II-2, II-4, II-10, III-3, and III-5 while it was
absent in Subjects II-6, II-7, II-9, III-1, and III-4. The
remaining members of the pedigree were not tested. The
microduplication, encompassing eleven known genes, was
confirmed by home-designed MLPA assay (data not
shown). FISH analysis performed in Patient II-2 only
showed specific signals on 1q22 chromosome for test probe
and on 1p36.33 chromosome for the control probe suggest-
ing a tandem arrangement of the duplication (data not
shown) .
Discussion
Constitutional duplications involving chromosome 1q22
have seldom been described. The familial 1q22 microdu-
plication here reported segregates with the core clinical
features of the affected members characterized by intel-
lectual disability and/or psychiatric disturbances includ-
ing general anxiety disorder, and mood disorders.
Interestingly, two adult affected females also showed late
onset (first clinical manifestations in their late twenties)
autoimmune inflammatory responses characterized by
skin ulcers secondary to inflammatory vasculitis, intersti-
tial lung disease, and Raynaud ? s phenomenon. These late
onset inflammatory traits are neither present in the
younger affected family members, nor in the maternal
grandmother of the propositus either suggesting that the
1q22 microduplication has an age-related penetrance or it
is unlinked to the inflammatory trait. At the time of writing,
comparable or larger duplications were not listed in DGV
whereas a similar, overlapping microduplication (Figure 3B)
was reported in the Decipher database (https://decipher.
sanger.ac.uk/index) in an individual with downslanted
palpebral fissures, joint hypermobility, microcephaly, and
Figure 3 Array-CGH analysis in the proband. A) Array-CGH profile revealing the 1q22 microduplication. Red dots represent duplicated
probes. B) Schematic representation of the genomic background of the 1q22 microduplication adapted from the human genome
browser (http://genome.ucsc.edu/).
Fichera et al. Molecular Cytogenetics 2014, 7:90 Page 4 of 6
http://www.molecularcytogenetics.org/content/7/1/90scapular winging. The rearrangement was also present
in his, similarly affected, mother. Chan et al. [3] de-
scribed a constitutional 1q (q11q22) duplication identi-
fied by comparative genomic hybridisation in a patient
with T lymphoblastic lymphoma/leukaemia with no
other developmental defects. Interestingly, the re-
arrangement was also present in his healthy mother and
sister. While these findings suggest that the duplication
of this region may be tolerated, it should be noted that
the precise boundaries and the exact gene content of
the rearrangement were not defined.
The rearrangement identified in our study involves
eleven known genes (ARHGEF2, RXFP4, LAMTOR2,
SSR2, RAB25, UBQLN4, MEX3A, LMNA, SLC25A44,
PMF1, and SEMA4A). Review of the literature led us to
consider LAMTOR2, LMNA, and SEMA4A as the stron-
gest candidate genes, although we cannot exclude that
dosage imbalance of other genes implicated in the re-
arrangement may contribute to the disease.The p14 protein, encoded by LAMTOR2, belongs to the
LAMTOR complex which is involved in the activation of
the extracellular signaling-regulated kinase (ERK1/2) and
the mTOR complex 1 (mTORC1). This protein is also ac-
tive in the regulation of endosomal trafficking, growth fac-
tor signaling and cell proliferation [4]. A homozygous
LAMTOR2 mutation was found in the affected members
of a family segregating a primary immunodeficiency syn-
drome, highlighting the important role of the p14 protein
in the immunological processes [5]. The mTOR pathway
holds an important immunoregulatory function as it acti-
vates conventional T cell and the proliferation of regula-
tory T cells. Several reports have recently demonstrated
that rapamycin, a potent inhibitor of mTOR, may attenu-
ate autoimmune responses reducing lymphoproliferation
[6]. However, there are no clear evidence that activation of
mTOR may trigger autoimmune manifestations. Recent
studies have suggested a link between mTor signaling and
synaptic plasticity, memory and neurological disease
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and a subsequent mTOR pathway dysregulation may
contribute to the neuropsychiatric traits observed in our
patients [7].
Through the use of alternative RNA splicing mechan-
ism the LMNA gene codes for A-type lamin proteins,
essentially lamin A and C. These two proteins are the
main structural elements of the nuclear envelope that
protects the nucleus from mechanical stress [8]. Besides
this role in the maintenance of the structural integrity of
the nucleus, lamin proteins are also important in several
biological processes such as DNA replication and chro-
matin organization [9]. While several missense or truncat-
ing mutations of the LMNA gene are associated with
muscular diseases, lipodistrophy syndromes and periph-
eral neuropathy, a specific synonymous mutation (G608G)
is the most common mutation identified in the premature
aging syndrome Hutchinson-Gilford progeria (HGPS
MIM 176670), a severe multisystemic disorder character-
ized by short stature, low body weight, early loss of hair,
lipodystrophy, scleroderma, and cardiovascular defects
[10]. The G608G mutation activates a cryptic splice site in
exon 11 leading to an abnormal mRNA that encodes a
protein called progerin which lacks the ZMPSTE24 cleav-
age site and remains farnesylated. The main pathophysio-
logical mechanism in HGPS seems related to the toxicity
of the farnesylated progerin which cannot incorporate
normally in the nuclear lamina causing nuclear morph-
ology defects and changes in gene expression and DNA
repair [11]. Homozygous or compound heterozygous
mutations in the ZMPSTE24 gene have been identified in
patients affected by HGPS-like disorder such as restrictive
dermopathy (RD 275210) and mandibuloacrodysplasia
with type B lipodystrophy (MADB; 608612). Either a
complete (RD syndrome) or partial (MADB syndrome)
loss of function of ZMPSTE24 leads to an accumulation
of farnesylated prelamin A which cannot produce mature
lamin A. These findings underline how both accumulation
of mutant farnesylated progerin and wild-type farnesylated
prelamin A are toxic. Interestingly, our patients show clin-
ical signs that also occur in the progeroid-like syndromes
such as vascular damage, scleroderma, and alopecia. These
observations raise the question of whether gene dosage in-
crease of LMNA in our patients may perturb the metabol-
ism of lamin A leading, at least in certain tissues, to an
accumulation of the farnesylated prelamin A which in turn
produces a tissue damage.
While duplications of lamin B coding gene, LMNB1
leads to adult-onset autosomal dominant leukodystrophy
(ADLD) [12], duplications of the LMNA locus has so far
not yet been associated with human diseases. However,
some reports have recently demonstrated using cellular
models that small perturbations in the metabolism of
wild-type lamin A induce nuclear defects and result in aprogeroid phenotype. Candelario et al. [13] showed that
overexpression wild-type lamin A in normal human
cells result in nuclear membrane defects and decreased
replicative lifespan. These findings have also been con-
firmed by Huang et al. [14] in fibroblast cell lines over-
expressing LMNA and showing telomere shortening
and nuclear damages. The authors also hypothesized
that duplications affecting the LMNA locus may result
in progeroid-like phenotypes in carrier individuals.
Taken together these observations suggest that the
LMNA gene duplication may contribute to the clinical
features of our patients.
The SEMA4A gene encodes a member of the sema-
phorin family whose members are involved in axon
guidance, morphogenesis, carcinogenesis, and immuno-
modulation. Mutations in that gene have been associ-
ated with retinitis pigmentosa (OMIM 610282) and
cone dystrophy (OMIM 610283). SEMA4A plays an im-
portant role in T cell activation and Th1 differentiation,
contributing to adaptive immunity. Although its exact
role in autoimmune disease is still to define, studies on
experimental autoimmune encephalomyelitis and myo-
carditis have demonstrated a critical role of SEMA4A by
regulating T-cell differentiation [15]. Moreover, a recent
study suggests that SEMA4A is involved in the patho-
genesis of Multiple Sclerosis and that high levels of
Sema4A are associated with a more severe clinical
manifestation of the disease [16].
Conclusions
The 1q22 microduplication that here we report belongs
to a group of candidate CNVs including very rare, often
inherited, imbalances which are both not present in the
general population and never reported in the literature.
Although caution is always necessary in the clinical in-
terpretation of those CNVs, in our family the rearrange-
ment segregates with the neurological clinical features
observed in our patients, strengthening its potential
pathogenic role. On the other hand, the association
between the microduplication and the inflammatory
disease is much less evident since the late onset of the
disease prevents any genotype-phenotype correlation in
the youngest members of the pedigree. Clinical follow-
up of these individuals and additional reported patients
carrying similar microduplications are needed to clarify
this aspect.
Methods
Array-CGH/SNP analysis was performed using the Cyto-
Chip Oligo SNP 4x180K kit (Bluegnome Ltd) containing
about 150,000 CGH probes and 27,000SNP probe pro-
viding an average resolution of 25 kb. Normal Human
male and female DNAs (Agilent Technologies) were
used as references. Array images were processed by the
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CNVs calls were identified with the Genomic Workbench
software 7.0 (both from Agilent Technologies) using
the aberration detection statistical algorithm ADM-2
(sensitivity threshold 4). CNVs presenting less than 4
consecutive probes with an absolute value less than 0.4
or present in at least 3 independent studies in the
database of Genomic Variants Database of Genomic
Variants (DGV: http://dgv.tcag.ca/dgv/app/home), were
filtered out from the rest of the analysis. Fluorescent in
situ hybridization (FISH) experiment was performed on
metaphase chromosome by standard techniques using
BAC insert clone RP11-172I6 mapping inside the dupli-
cated region and RP11-54O7 as control clone for the
1p chromosome (BlueGnome, Technogenetics). Multiple-
ligation-probe amplification (MLPA) A locus specific assay
was designed and performed in the propositus, in the
other members of the pedigree and in ten normal individ-
uals (reagents and enzyme were from MRC-Holland,
Amsterdam, Netherlands). Amplicons were recognized
and quantified by capillary electrophoresis on an ABI 3130
GeneticAnalyser (Applied Biosystems, Foster City, CA).
The tracing data were then normalized by dividing each
probe? s peak area by the average area of all peaks of the
sample and then dividing this value by the average
normalized peak? s area of the corresponding locus of all
the samples.
Consent
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their parents for publication of this paper and any
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